繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-6

MB-6

Indication
Acting as Adjuvant for metastatic colorectal cancer
Product Advantages
reducing chemo-associated toxicity and enhancing efficacy of chemotherapy
Status
Phase III clinical trial is in progress
Competitive Edge
Oral capsule botanical drug, high safety, not much similar drugs currently on the market or under development
Potential Market
The analysis by GBI Research points out that the market value of colorectal cancer treatment will increase from 8.3 billion U.S. dollars in 2013 to 9.4 billion U.S. dollars in 2020
  • A series of preclinical studies had demonstrated that MB-6 reduced the incidence of colonic polyps and formation of tumor, prolonged survival rate as compared to chemotherapy alone when MB-6 was given together with 5-FU in colorectal cancer bearing mice.
  • MB-6 obtained USFDA and Taiwan Ministry of Health and Welfare (MOHW) phase II IND approval. In the Phase II clinical trials of patients with colorectal cancer in Taiwan, the combination of MB-6 and FOLFOX-4 standard treatment significantly prolonged progression-free survival (PFS) and overall survival, improved chemotherapeutic compliance, and improved FOLFOX-4-induced Neutropenia and reduce the dose of granulocyte colony stimulating factor (G-CSF) used

Phase II clinical trial


陕西快乐十分中奖技巧 亚马逊币交易平台 彩票平台骗子 cmd体育进不去 河内5分彩开奖记录 足彩半全场玩法规则 沙巴体育平台有哪些 帝苑娱乐平台 体彩山东快乐扑克3今天 陕西11选5全部奖金图表 网上麻将赌博 北京快三遗漏数据库 极速11选5开奖 - 点击进入 2021以太坊价格 期期中大奖 比特币软件 中国福彩22选5号码预测